 | 
 | |
2NTX-99, is a small molecule anti-platelet, anti-atherothrombotic agent with nitric oxide (NO) donating properties currently in preclinical development. Mechanistically, 2NTX-99 inhibits the synthesis and action of thromboxane and enhances prostacyclin production. Prostacyclin and NO work together to inhibit platelet adhesion and aggregation, induce vasodilation and protect the vascular wall from atherogenic stimuli. Nile believes that this unique profile could enable 2NTX-99 treating a range of atherosclerotic, thrombotic and microvascular diseases, including diabetic nephropathy and intermittent claudication. 2NTX-99 is currently undergoing IND-enabling pre-clinical and toxicology studies. We expect to initiate Phase I studies in 2009.
| |
|
